Acquisitions, Mergers & PartnershipsBioprinting

CELLINK announces partnership with biotech company Lonza

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

Swedish bioprinting firm CELLINK has announced it has formed an alliance with Swiss chemicals and biotech company Lonza. Through the agreement, the partners will combine CELLINK’s 3D bioprinting systems and bioinks with Lonza’s primary cells and culture media to offer a complete 3D bioprinting solution for 3D cell culture workflows. The solution is intended for cell biologists and other researchers pushing the boundaries of bioprinting and human tissue generation.

“Everything we do at CELLINK, from live cell imaging to our innovative bioprinting systems and bioinks, is meant to support our customers with the products and services needed for them to more effectively and efficiently research solutions to some of the most important challenges of our time,” commented Ginger Lohman, Biodispensing Product Manager at CELLINK. “Challenges such as cancer therapeutics, regenerative medicine and the testing and development of drugs, to name a few. When it came time to expand our portfolio into complete 3D cell culture workflows, we knew it was critical that we brought the right partner onboard. We’re confident that Lonza is that partner.”

CELLINK Lonza partnership
The Bio X system from CELLINK

Through the partnership, CELLINK will offer the complete 3D bioprinting solution through its established global sales channels with support from Lonza’s expert logistics processes. The companies hope the offering will help meet a growing demand from cell biology labs for 3D cell culture technologies, which more closely mimic in vivo environments than more traditional 2D cell culture methods.

“Cell biology laboratories are constantly seeking innovative new technologies to enhance their experimental workflows and help deliver on their promise to drive the next research breakthrough,” added Katrin Hoeck, Head of Marketing for Cell Analysis and Testing Solutions at Lonza. “Our broad panel of human-derived primary cells is specifically engineered to enable researchers to develop biological in vitro model systems that more closely reflect disease biology. This new collaboration with CELLINK will enable our customers to build physiologically-relevant 3D models to accelerate target identification/validation, investigation of mechanisms of action and safety testing in drug discovery.”

Lonza’s portfolio of human-derived primary cells will complement CELLINK’s array of bioprinting systems and its universal bioink material. Robust and viable cells are an important part of the bioprinting equation, and Lonza’s products are all ethically sourced and authenticated through quality control testing. Its culture media products are themselves optimized for each cell type to support optimal cell growth.

Composites AM 2024

746 composites AM companies individually surveyed and studied. Core composites AM market generated over $785 million in 2023. Market expected to grow to $7.8 billion by 2033 at 25.8% CAGR. This new...

Tess Boissonneault

Tess Boissonneault is a Montreal-based content writer and editor with five years of experience covering the additive manufacturing world. She has a particular interest in amplifying the voices of women working within the industry and is an avid follower of the ever-evolving AM sector. Tess holds a master's degree in Media Studies from the University of Amsterdam.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close Popup
Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

Technical Cookies
In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services


Join our 12,000+ Professional community and get weekly AM industry insights straight to your inbox. Our editor-curated newsletter equips executives, engineers, and end-users with crucial updates, helping you stay ahead.